Tag Archives: pharmaceutical grade

From The Lab

What Food-Safety Teams Should Ask a Cannabinoid Supplier

By Vaughn Hartung
1 Comment

The cannabinoid industry has historically focused heavily on manufacturing compliance: GMPs, certificates of analysis, potency testing, contaminant testing, traceability, and state licensing. Those systems are important, and Floraworks has invested significantly in them. But when you begin evaluating an ingredient through established food and dietary supplement frameworks, you realize that manufacturing compliance is really just the starting point.

Floraworks has spent the last several years evaluating cannabinol (CBN) as a mainstream food and dietary ingredient. The biggest lesson was that being a compliant cannabinoid supplier and having a qualified ingredient are two very different standards. The first answers, “Did this batch pass its COA?” The second answers a much larger question: “What evidence supports the safety and identity of this ingredient for its intended use?”

 

Start With a Better Question

“Is CBN safe?” is the start of a larger scientific discussion. Specifically, safe at what exposure, under what conditions of use, for what population, and supported by what evidence?

Established frameworks such as GRAS and the New Dietary Ingredient (NDI) pathway are built to answer that kind of question. We have spent significant time evaluating CBN for both. Working through these frameworks requires a much more complete picture of an ingredient than the cannabinoid industry has historically had to develop.

Here is how I would evaluate a cannabinoid supplier from a quality perspective.

 

1. Verify the Quality Foundation

Start by separating basic supplier qualification from ingredient qualification. Absolutely verify the quality-management system, GMP status, traceability, analytical testing, specifications, and manufacturing controls. Those remain essential. Then go further.

 

2. Ask the Supplier to Define the Ingredient

CBN is a defined molecule. A commercial ingredient is more than the name of its principal constituent. How it is manufactured, its purity, its specifications, its impurity profile, and its consistency all matter when you are connecting scientific evidence to the material consumers will actually receive.

Ask the supplier to define the ingredient precisely. Ask how it is manufactured, what controls exist around potential impurities and degradation products, and whether stability data supports the specification.

There are multiple ways to produce and purify cannabinoids. From a scientific perspective, you need to understand what the resulting ingredient is, what else may be present, and whether the evidence represents that ingredient.

 

3. Connect the Evidence to the Commercial Material

The value of the evidence depends on the ability to connect it to the commercial ingredient. If toxicology is conducted on one material, clinical research on another, and the commercial ingredient has materially different specifications, it becomes much harder to understand what the evidence actually supports.

Ask whether toxicology research was performed on the commercial ingredient or a representative test article and if the findings are available for review.

Serious ingredient development has to start with chemistry and manufacturing: defined specifications, analytical methods, control over the manufacturing process, an understanding of impurities and contaminants, and enough consistency to know that the material sold today remains representative of the material. For Floraworks, standardization is crucial to our ingredient supply.

 

4. Understand Intended Use and Exposure

Dose, intended use, and consumer exposure are fundamental. What is the proposed serving amount? How frequently will it be consumed, in what types of products, and by what population? What is the resulting anticipated daily intake? What daily exposure does the supplier believe the evidence supports, and how did it reach that conclusion?

The same ingredient could be used at very different concentrations and frequencies across product categories. A safety conclusion developed around one set of conditions shouldn’t automatically be extrapolated to every other possible use. More is not necessarily better. Our current GRAS evaluation is built around specifically defined intended uses and exposure conditions for that reason.

 

5. Evaluate the Safety Package as a Whole

Ask what toxicology research has actually been conducted, and what peer-reviewed evidence exists.

Floraworks own safety program includes GLP toxicology work and genotoxicity evaluation. Our 90-day repeated-dose oral toxicology study established a no-observed-adverse-effect level (NOAEL) of 400 mg/kg body weight per day in an oral exposure model. One of our biggest lessons has been to avoid viewing a single number as the safety story. A NOAEL has to be interpreted in the context of the study design, the test material, intended human exposure, the broader peer-reviewed scientific literature, and other available safety information.

Working through a formal safety assessment demonstrates what the evidence supports, where it is limited, and where additional testing may be warranted. The customer-focused question that shapes our research program is: “What additional research needs to be performed to better inform the consumer?”

 

6. Keep Safety and Efficacy Distinct

Pre-clinical research and ingredient safety are distinct but complementary topics. Pre-clinical research determines the end use, dosing, tolerability, and potential benefit. Safety studies address topics such as suggested dosage, repeated use, and tolerability. Chemistry and manufacturing establish identity and consistency. Where benefits are claimed, they should be supported by appropriate evidence.

 

7. Ask Which Regulatory Framework Supports the Use

Finally, ask what regulatory framework the supplier believes supports the intended use and what work has actually been done to evaluate that position.

GRAS relates to the safety of a substance under its intended conditions of use in food. The NDI framework addresses new dietary ingredients intended for use in dietary supplements. The evidence can overlap substantially. The regulatory context and the questions each framework addresses are distinct. Floraworks has evaluated both pathways in parallel, and we are still working through those processes.

 

What the Answers Tell You

Are you buying an ingredient with unknown origin that comes with a generic COA from a broker, or working with a supplier that is developing qualified market-ready ingredients?

Non-intoxicating cannabinoids should ultimately be evaluated using established safety frameworks wherever those frameworks can appropriately apply. That gives regulators, manufacturers, brands, and consumers a common scientific language for evaluating these ingredients.

 

Where the Industry Needs to Go

Cannabinoids need to stop being treated as siloed products from other food and dietary ingredients. There exists a wide diversity of molecules in cannabis sativa, and we are only beginning to understand their specific therapeutic value. That scientific interest increases our responsibility to characterize and develop these molecules properly.

Our current industry should have clearly defined ingredients, controlled manufacturing processes, reproducible specifications, appropriate toxicology research, scientifically justified exposure levels, and regulatory strategies appropriate to the intended use.

FloraWorks began as a cannabinoid specialist. Increasingly, the FloraWorks team and I have had to think like a traditional ingredient company, a food-safety organization, and a scientific development company at the same time. I believe that is where the broader cannabinoid industry ultimately needs to go.

 

Soapbox

How Rare Cannabinoids Will Impact Investing

By Maxim Mikheev, Dennis O’Neill
No Comments

There is a significant increase in demand for all cannabinoid products across the board—including CBD, THC, CBG and THCV—from recreational users, consumer packaged goods and pharmaceutical companies. And the next great race is on for the hottest arrival to scientific cannabis therapeutics: rare cannabinoids.

Research shows rare cannabinoids are poised to be the future of cannabis investing, providing better health benefits in addition to impacting the pharmaceutical, CPG, nutraceuticals, cosmetics and pet care markets significantly. According to recent reports, the biosynthesis of rare cannabinoids will be a $25 billion market by 2025 and $40 billion by 2040.

The companies that will revolutionize this market are ones with the highest quality and lowest prices, which means that biosynthetic cannabinoid companies will be the leaders in investment and capturing market share. We will also see a major consolidation in this market amongst the grow, harvest and extraction companies, increasing efficiencies and driving down costs.

What are rare cannabinoids and why should we care?

Tetrahydrocannabivarin (THCV)

Rare cannabinoids such as CBG, CBN, THCV, THCA and others have significantly better and more specific health benefits than just CBD on its own. Biotech companies like ours, Biomedican, which has a patent-pending biosynthesis platform, can produce pharmaceutical grade, non-GMO, bioidentical, synthetic cannabinoids with 0.0% THC at 70-90% less cost. Producing 0.0% THC means that rare cannabinoids can be added into nutraceuticals, CPG and cosmetics/lotions with zero changes in current cannabis regulations. Also, we produce the same exact product every time (not possible through plants), which is extremely important for pharmaceutical companies conducting clinical trials.

Why are rare cannabinoids important?    

The human body contains different cannabinoid receptors that help regulate critical processes, including learning, memory, neuronal development, appetite, digestion, inflammation, overall mood, sleep, metabolism and pain perception. This considerable involvement of cannabinoid receptors, critical to many physiological systems, underscores their potential as pharmaceutical targets.

Tetrahydrocannabinol (THC), just one of hundreds of cannabinoids found in cannabis.

Pharmacological research has uncovered several medical uses for cannabinoids, which bind to cannabinoid receptors. They’ve been shown to help with pathological conditions such as pediatric epilepsies, glaucoma, neuropathic pain, schizophrenia and have anti-tumor effects as well as promote the suppression of chemotherapy-induced nausea. This ongoing research is becoming more prevalent and has the potential to uncover therapeutic uses for an array of cannabinoids.

In addition to the medical field, other prominent sectors have adopted the use of cannabinoids. There is an increasing demand for cannabinoids in inhalables, the food industry and in hygienic and cosmetic products. Veterinary uses for cannabinoids are also coming to light. The use of naturally occurring cannabinoids reduces the need for synthetic alternatives that may produce harmful off-target effects. 

So how does this affect the investing market?

Where there is demand, significant and growth investments follow. All the major players from nutraceuticals, CPG, cosmetics and pet care companies are driving the demand for rare cannabinoids. We are seeing a major investment shift from commodity-based prices for cannabis and CBD to the new biosynthesis technology which offers significantly better health benefits and higher profit margins. Those unique qualities of rare cannabinoids open an enormous opportunity to create new drugs and food supplements for treating various medical conditions and improving the quality of life. This creates a massive global opportunity for all companies in these categories differentiating their products from competitors.

The structure of cannabidiol (CBD)

There will be big winners and losers in these markets, but at the end of the day, the highest quality and lowest cost producers will capture most of these markets. Biomedican has the highest quality, highest yields and lowest cost of production in the industry. Which we believe will make us the clear leader in the biosynthesis rare cannabinoid markets.

Which rare cannabinoid to invest in first?

Early reports indicate THCV (not to be confused with THC) could contain a variety of health benefits: it may help with appetite suppression/weight loss, possibly treat diabetes as well the potential to reduce tremors and seizures caused by conditions like multiple sclerosis, Parkinson’s disease and ALS.

There has been an explosion of interest in THCV due to its potential health benefits. We are seeing major players in the nutraceutical, health food and pharmaceutical industries clamoring to add THCV to their product lines. Companies can now produce THCV through biosynthesis, creating a pharmaceutical-grade, organic, bioidentical compound at 70-90% less than wholesale prices. This is exactly what the largest players in the market want: a pharmaceutical-grade, consistent product at significantly less cost. The current prices and quality have limited THCV production, but new breakthroughs in biosynthesis have solved those issues, so we expect a tsunami of orders for THCV in 2021.